Since she joined the staff at the Dana-Farber Cancer Institute in 2000, she has initiated an integrated program of research and clinical activities that focuses on dissecting the underlying mechanisms of pathobiology of chronic lymphocytic leukemia as a means to more rationally generate effective therapies, including immune-based treatments, for this common adult leukemia. She has been principal investigator of several center-initiated clinical trials. A major priority of her studies is the identification of tumor-specific antigens that would allow effective tumor targeting without collateral toxicity. She has been using exome and transcriptome sequencing technologies to identify unique mutated leukemia antigens that arise from individual-specific genetic alterations within a tumor and that could be potentially targeted immunologically, thus paving the way for developing personalized tumor vaccines.